Department of Pathology
  Brigham and Women's Hospital
  A teaching Affliate of Harvard Medical School
Login Skip Navigation Links
  Skip Navigation Links
HomeExpand Home





Announcement

Submit new announcement
Stacy E.F. Melanson, M.D.,Ph.D.

Assistant Professor of Pathology, Harvard Medical School
Associate Medical Director, Clinical Chemistry
Medical Director, Phlebotomy
Director, BWH Laboratory at BWH/Mass General Health Care Center
Academic Activities:
I am a clinical pathologist with research interests that currently include cardiac markers, laboratory utilization and operations, and toxicology.
Office
75 Francis Street
AL-2-236a Amory building
Boston,MA 02115
Email1: semelanson@partners.org
Education and Training:

Medical School - 2002 : Tufts University School of Medicine
Internship/Residency 6/02 - 2004 : Massachusetts General Hospital

Clinical Specialties:
  • Clinical Chemistry
Research Interests:
  • Marker identification
  • Targeted therapy
  • Toxicology
  • Pharmacogenomics
  • Process Improvement
Publication:
  1. Melanson SEF, Szymanski T, Rogers SO, Jarolim P, Frendl G, Rawn JD, Cooper Z, Ferrigno M. Utilization of arterial blood gas measurements in a large tertiary care hospital. Am J Clin Pathol 2007;127:604-609.
  2. Melanson SEF, Lindeman NI, Jarolim P. Selecting automation for the clinical chemistry laboratory. Arch Pathol Lab Med 2007;131:1063-1069.
  3. Melanson SEF, Morrow DA, Jarolim P. Earlier detection of myocardial injury in a preliminary evaluation using a new troponin I assay with improved sensitivity. Am J Clin Pathol 2007;128:282-286.
  4. Melanson SEF, Lee Lewandrowski E, Griggs DA, Flood JG. Interpreting tricyclic antidepressant measurements in urine in an emergency department setting: Comparison of two qualitative point-of-care urine tricyclic antidepressant drug immunoassays with quantitative serum chromatographic analysis. J Anal Toxicol 2007;31:270-275.
  5. Melanson SEF, Conrad MJ, Mosammaparast N, Jarolim P. Implementation of a highly sensitive cardiac troponin I assay: test volumes, positivity rates and interpretation of results. Clin Chim Acta 2008;395:57-61.
  6. Melanson SEF, Kredlow MI, Jarolim P. Analysis and interpretation of drug testing results from patients on chronic pain therapy: A clinical laboratory perspective. Clin Chem Lab Med, 2009;47:971-976.
  7. Melanson SEF, Goonan EM, Lobo MM, Baum JM, Paredes JD, Santos KS, Gustafson ML, Tanasijevic MJ. Applying Lean/Toyota Production System principles to improve phlebotomy patient satisfaction and workflow. Am J Clin Pathol, 2009;132:914-919.
  8. Melanson SEF, Baskin L, Magnani BJ, Kwong, TC, Wu, AHB. Interpretation and utility of drug of abuse immunoassays: lessons from laboratory drug testing survey. Arch Pathol Lab Med, in press.
  9. Morrison A, Tanasijevic MJ, Goonan E, Lobo M, Bates M, Lipsitz S, Bates D, Melanson SEF. Reduction in specimen labeling errors after implementation of a positive patient identification system in phlebotomy. Am J Clin Pathol, in press.
<October 2017>
SuMoTuWeThFrSa
24252627282930
1234567
891011121314
15161718192021
22232425262728
2930311234


<Friday, October 20, 2017>
8:00 AM
Dr. Maria Kuba, Dr. Yi Daniel Li
Cotran Conference Center
9:15 AM

Autopsy suite
12:00 PM

GYN 14-headed scope
1:00 PM
Dr. Christopher Fletcher
Cotran Conference Center
Copyright 2008 - 2017, BWH Pathology, All rights reserved.